Title of article
FOLFIRI Combined with Bevacizumab as First-Line.Treatment for Metastatic Colorectal Cancer Patients with Hyperbilirubinemia after UGT1A1 Genotyping
Author/Authors
Yeh, Yung-Sung Kaohsiung Municipal Hsiao-Kang Hospital - Department of Emergency Medicine, Department of Surgery, Taiwan , Huang, Meng-Lin ZuoYing Armed Forces General Hospital - Department of Surgery, Taiwan , Chang, Se-Fen Kaohsiung Municipal Hsiao-Kang Hospital - Department of Nursing, Taiwan , Chen, Chin-Fan Kaohsiung Municipal Hsiao-Kang Hospital - Department of Emergency Medicine, Department of Surgery, Taiwan , Hu, Huang-Ming Kaohsiung Medical University Hospital - Department of Internal Medicine, Taiwan , Wang, Jaw-Yuan Kaohsiung Medical University Hospital - Cancer Center - Department of Surgery, Taiwan
From page
478
To page
481
Abstract
Objective: To report a metastatic colorectal cancer patient with hyperbilirubinemia treated with a combination of bevacizumab and FOLFIRI (5-fluorouracil, leucovorin, and irinotecan) using uridine diphosphate glucuronosyl transferase (UGT1A1) genotyping. Clinical Presentation and Intervention: A 46-year-old male was diagnosed with rectosigmoid colon cancer with liver metastases and hyperbilirubinemia presenting with severe jaundice. UGT1A1 genotyping was used before therapy to ascertain whether genotype-adjusted dosages of irinotecan plus bevacizumab could alleviate the toxicity. Then, the patient was treated with FOLFIRI. Conclusion: The FOLFIRI regimen was successfully used in this patient without concerns regarding toxicity.
Keywords
UGT1A1 · Liver dysfunction · Hyperbilirubinemia · FOLFIRI · Bevacizumab
Journal title
Medical Principles and Practice
Journal title
Medical Principles and Practice
Record number
2575606
Link To Document